Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-6405
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance ; volume:18 ; number:1 ; day:8 ; month:9 ; year:2021 ; pages:1-5 ; date:12.2021
AIDS research and therapy ; 18, Heft 1 (8.9.2021), 1-5, 12.2021
- Creator
-
Wolf, Eva
Boesecke, Christoph
Balogh, Annamaria
Bidner, Helen
Cordes, Christiane
Heiken, Hans
Krznaric, Ivanka
Kümmerle, Tim
Stellbrink, Hans-Jürgen
Schneider, Jochen
Spinner, Christoph Daniel
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12981-021-00384-6
- URN
-
urn:nbn:de:101:1-2021112218264721268347
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wolf, Eva
- Boesecke, Christoph
- Balogh, Annamaria
- Bidner, Helen
- Cordes, Christiane
- Heiken, Hans
- Krznaric, Ivanka
- Kümmerle, Tim
- Stellbrink, Hans-Jürgen
- Schneider, Jochen
- Spinner, Christoph Daniel
- SpringerLink (Online service)
Other Objects (12)
Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
Modifying dolutegravir to PrEPare for long life
Use of new resistance markers to predict virologic response to antiretrovirals
RESPECT TO RMC!
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV
Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
Isotype Heterojunction-Boosted CO2 Photoreduction to CO
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting
HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir
The last tribute to respect
Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
Modifying dolutegravir to PrEPare for long life
Use of new resistance markers to predict virologic response to antiretrovirals
RESPECT TO RMC!
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV
Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
Isotype Heterojunction-Boosted CO2 Photoreduction to CO
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting
HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir
The last tribute to respect
Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
Modifying dolutegravir to PrEPare for long life
Use of new resistance markers to predict virologic response to antiretrovirals
RESPECT TO RMC!
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV
Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
Isotype Heterojunction-Boosted CO2 Photoreduction to CO
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting
HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir